Jörg Schüttrumpf

922 total citations
39 papers, 588 citations indexed

About

Jörg Schüttrumpf is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Jörg Schüttrumpf has authored 39 papers receiving a total of 588 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 14 papers in Molecular Biology and 10 papers in Genetics. Recurrent topics in Jörg Schüttrumpf's work include Platelet Disorders and Treatments (9 papers), Hemophilia Treatment and Research (8 papers) and Virus-based gene therapy research (7 papers). Jörg Schüttrumpf is often cited by papers focused on Platelet Disorders and Treatments (9 papers), Hemophilia Treatment and Research (8 papers) and Virus-based gene therapy research (7 papers). Jörg Schüttrumpf collaborates with scholars based in Germany, United States and United Kingdom. Jörg Schüttrumpf's co-authors include Erhard Seifried, Patricia Quade-Lyssy, Martin König, Heinfried H. Radeke, Daniela Abriss, Christoph Königs, Reinhard Henschler, Matthias Germer, Ulrike Köhl and Herbert Watzke and has published in prestigious journals such as Blood, PLoS ONE and Hepatology.

In The Last Decade

Jörg Schüttrumpf

36 papers receiving 579 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jörg Schüttrumpf Germany 14 205 166 135 124 99 39 588
Patricia Garrido Castro Spain 16 229 1.1× 103 0.6× 310 2.3× 98 0.8× 148 1.5× 54 791
Thomas B. Okarma United States 12 234 1.1× 101 0.6× 139 1.0× 187 1.5× 91 0.9× 21 527
Tiffany Tate United States 10 295 1.4× 151 0.9× 142 1.1× 132 1.1× 140 1.4× 18 646
K Iida Japan 10 202 1.0× 88 0.5× 270 2.0× 48 0.4× 86 0.9× 17 724
Sandhya R. Panch United States 17 272 1.3× 232 1.4× 150 1.1× 119 1.0× 310 3.1× 70 894
T Shikano Japan 16 216 1.1× 177 1.1× 71 0.5× 255 2.1× 227 2.3× 28 648
Gisela Cáceres United States 15 360 1.8× 195 1.2× 350 2.6× 32 0.3× 118 1.2× 27 787
Takao Kodera Japan 13 138 0.7× 78 0.5× 90 0.7× 121 1.0× 44 0.4× 31 606
Jonathan E. Brammer United States 16 179 0.9× 210 1.3× 295 2.2× 36 0.3× 423 4.3× 112 888
Takeki Mitsui Japan 14 236 1.2× 203 1.2× 222 1.6× 40 0.3× 113 1.1× 60 688

Countries citing papers authored by Jörg Schüttrumpf

Since Specialization
Citations

This map shows the geographic impact of Jörg Schüttrumpf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jörg Schüttrumpf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jörg Schüttrumpf more than expected).

Fields of papers citing papers by Jörg Schüttrumpf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jörg Schüttrumpf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jörg Schüttrumpf. The network helps show where Jörg Schüttrumpf may publish in the future.

Co-authorship network of co-authors of Jörg Schüttrumpf

This figure shows the co-authorship network connecting the top 25 collaborators of Jörg Schüttrumpf. A scholar is included among the top collaborators of Jörg Schüttrumpf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jörg Schüttrumpf. Jörg Schüttrumpf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bauhofer, Artur, et al.. (2024). Adequate IVIG dosing is associated with an improved long-term outcome in secondary immunodeficiency: A prospective, non-interventional study. International Journal of Clinical Pharmacology and Therapeutics. 62(10). 448–459.
3.
Singer, Mervyn, Antoní Torres, Andrea Wartenberg‐Demand, et al.. (2023). The immunomodulating activity of trimodulin (polyvalent IgM, IgA, IgG solution): a post hoc analysis of the phase II CIGMA trial. Critical Care. 27(1). 436–436. 7 indexed citations
4.
Germer, Matthias, et al.. (2023). Rising anti-SARS-CoV-2 titer in a human immunoglobulin preparation. 13(1). 1–8. 1 indexed citations
5.
Schmidt, Carolin, et al.. (2021). The Dual Role of a Polyvalent IgM/IgA-Enriched Immunoglobulin Preparation in Activating and Inhibiting the Complement System. Biomedicines. 9(7). 817–817. 10 indexed citations
6.
Schüttrumpf, Jörg, et al.. (2021). Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI. Frontiers in Immunology. 12. 700429–700429. 13 indexed citations
7.
Devlieger, Roland, Horst Buxmann, Gerardo Nigro, et al.. (2021). Serial Monitoring and Hyperimmunoglobulin versus Standard of Care to Prevent Congenital Cytomegalovirus Infection: A Phase III Randomized Trial. Fetal Diagnosis and Therapy. 48(8). 611–623. 14 indexed citations
8.
Schüttrumpf, Jörg, et al.. (2021). The Functional Role of IgA in the IgM/IgA-Enriched Immunoglobulin Preparation Trimodulin. Biomedicines. 9(12). 1828–1828. 6 indexed citations
9.
Schönfeld, Kurt, et al.. (2018). Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate. PLoS ONE. 13(4). e0195823–e0195823. 21 indexed citations
10.
Schönfeld, Kurt, et al.. (2018). Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models. Pharmaceutical Research. 35(6). 118–118. 19 indexed citations
11.
Quade-Lyssy, Patricia, et al.. (2014). Next generation FIX muteins with FVIII‐independent activity for alternative treatment of hemophilia A. Journal of Thrombosis and Haemostasis. 12(11). 1861–1873. 10 indexed citations
12.
Quade-Lyssy, Patricia, et al.. (2014). Oral gene therapy for hemophilia B using chitosan‐formulated FIX mutants. Journal of Thrombosis and Haemostasis. 12(6). 932–942. 12 indexed citations
13.
Abel, Tobias, Irene C. Schneider, Qinggong Yuan, et al.. (2013). Specific gene delivery to liver sinusoidal and artery endothelial cells. Blood. 122(12). 2030–2038. 44 indexed citations
14.
Quade-Lyssy, Patricia, Heinfried H. Radeke, Reinhard Henschler, et al.. (2013). Galectin-9 Is a Suppressor of T and B Cells and Predicts the Immune Modulatory Potential of Mesenchymal Stromal Cell Preparations. Stem Cells and Development. 23(7). 755–766. 82 indexed citations
15.
Quade-Lyssy, Patricia, et al.. (2012). Oral Gene Delivery of Factor IX Muteins Formulated As Chitosan Nanoparticles for the Treatment of Hemophilia B. Blood. 120(21). 2048–2048. 3 indexed citations
16.
Bönig, Halvard, M. Heiden, Jörg Schüttrumpf, Michael Müller, & Erhard Seifried. (2011). Potenzial hämatopoetischer Stammzellen als Ausgangsmaterial für Arzneimittel für neuartige Therapien. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz. 54(7). 791–796. 1 indexed citations
17.
Schüttrumpf, Jörg, et al.. (2010). Transgene Loss and Changes in the Promoter Methylation Status as Determinants for Expression Duration in Nonviral Gene Transfer for Factor IX. Human Gene Therapy. 22(1). 101–106. 15 indexed citations
18.
Heinz, Stefan, Jörg Schüttrumpf, Jeremy C. Simpson, et al.. (2009). Factor VIII-eGFP fusion proteins with preserved functional activity for the analysis of the early secretory pathway of factor VIII. Thrombosis and Haemostasis. 102(11). 925–935. 3 indexed citations
19.
Schüttrumpf, Jörg, et al.. (2008). Verträglichkeit und Wirksamkeit von DDAVP. Hämostaseologie. 28(S 01). S112–S112. 3 indexed citations
20.
Watzke, Herbert, Jörg Schüttrumpf, Senta Graf, Kurt Huber, & Simon Panzer. (1997). INCREASED PREVALENCE OF A POLYMORPHISM IN THE GENE CODING FOR HUMAN PROTHROMBIN IN PATIENTS WITH CORONARY HEART DISEASE. Thrombosis Research. 87(6). 521–526. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patricia Garrido Castro Breakdown of academic impact, for papers by Thomas B. Okarma Breakdown of academic impact, for papers by Tiffany Tate Breakdown of academic impact, for papers by K Iida Breakdown of academic impact, for papers by Sandhya R. Panch Breakdown of academic impact, for papers by T Shikano Breakdown of academic impact, for papers by Gisela Cáceres Breakdown of academic impact, for papers by Takao Kodera Breakdown of academic impact, for papers by Jonathan E. Brammer Breakdown of academic impact, for papers by Takeki Mitsui
Rankless by CCL
2026